Investigational drug · Phase 2
KUS121
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Central Retinal Artery Occlusion.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "KUS121"
First trial start
2024
Apr 16, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KUS121", any sponsor or status.
Conditions studied
As listed on its trial records.
- Central Retinal Artery Occlusion
Approved drugs for the same conditions: Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "KUS121" as an intervention, largest first.
Kyoto Drug Discovery and Development Co., Ltd.Industry
NCT06178055 · 17 participants · Start Apr 16, 2024 · Primary completion Mar 3, 2025
Drug: KUS121 high dose; KUS121 low dose and 1 more · For: Central Retinal Artery Occlusion
Sites: Encino, California; Huntington Beach, California; Oakland, California · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- "Protective effect of KUS121, a valosin-containing protein (VCP) modulator, against ischemia/reperfusion injury in axial pattern flaps".
Yoshimoto K, Ikeguchi R, Noguchi T, et al. · Plast Reconstr Surg 2026
- KUS121, a novel VCP modulator, attenuates atherosclerosis development by reducing ER stress and inhibiting glycolysis through the maintenance of ATP levels in endothelial cells.
Zou F, Baba O, Horie T, et al. · Atherosclerosis 2025
- Valosin-containing protein modulator KUS121 protects retinal neurons in a rat model of anterior ischemic optic neuropathy.
Kikkawa C, Ikeda HO, Hata M, et al. · Sci Rep 2025
- The effect of KUS121, a novel VCP modulator, against ischemic injury in random pattern flaps.
Yoshimoto K, Ikeguchi R, Noguchi T, et al. · PLoS One 2024
- KUS121, a VCP modulator, has an ameliorating effect on acute and chronic heart failure without calcium loading via maintenance of intracellular ATP levels.
Tsuji S, Otani C, Horie T, et al. · Biomed Pharmacother 2024
- A novel VCP modulator KUS121 exerts renoprotective effects in ischemia-reperfusion injury with retaining ATP and restoring ERAD-processing capacity.
Hata Y, Date R, Fujimoto D, et al. · Am J Physiol Renal Physiol 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.